News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
711,188 Results
Type
Article (43415)
Company Profile (345)
Press Release (667428)
Section
Business (211973)
Career Advice (2163)
Deals (37029)
Drug Delivery (102)
Drug Development (83912)
Employer Resources (173)
FDA (16610)
Job Trends (15525)
News (359165)
Policy (34330)
Tag
Academia (2608)
Alliances (51676)
Alzheimer's disease (1247)
Approvals (16518)
Artificial intelligence (137)
Bankruptcy (368)
Best Places to Work (11695)
Biotechnology (217)
Breast cancer (114)
Cancer (1009)
Cardiovascular disease (89)
Career advice (1801)
Cell therapy (218)
Clinical research (66431)
Collaboration (355)
Compensation (178)
COVID-19 (2618)
Data (954)
Diabetes (150)
Diagnostics (6230)
Drug pricing (95)
Earnings (86610)
Employer resources (152)
Events (113153)
Executive appointments (264)
FDA (17084)
Funding (310)
Gene therapy (167)
GLP-1 (637)
Government (4509)
Healthcare (18987)
Infectious disease (2703)
Inflammatory bowel disease (108)
Interviews (337)
IPO (16710)
Job creations (4156)
Job search strategy (1548)
Layoffs (445)
Legal (8458)
Lung cancer (167)
Manufacturing (173)
Medical device (13288)
Medtech (13293)
Mergers & acquisitions (20346)
Metabolic disorders (425)
Neuroscience (1507)
NextGen Class of 2024 (6712)
Non-profit (4538)
Northern California (1316)
Obesity (255)
Opinion (219)
Patents (103)
People (58637)
Pharmaceutical (101)
Phase I (20639)
Phase II (29184)
Phase III (21893)
Pipeline (323)
Postmarket research (2673)
Preclinical (8734)
Radiopharmaceuticals (243)
Rare diseases (204)
Real estate (6347)
Regulatory (22638)
Research institute (2380)
Resumes & cover letters (370)
Southern California (1171)
Startups (3778)
United States (12546)
Vaccines (572)
Weight loss (205)
Date
Today (233)
Last 7 days (1079)
Last 30 days (3360)
Last 365 days (36413)
2024 (32017)
2023 (40928)
2022 (52113)
2021 (56676)
2020 (55113)
2019 (47825)
2018 (36140)
2017 (33570)
2016 (33169)
2015 (39009)
2014 (32960)
2013 (28077)
2012 (30165)
2011 (30871)
2010 (28889)
Location
Africa (804)
Arizona (197)
Asia (40886)
Australia (6479)
California (2977)
Canada (1217)
China (231)
Colorado (129)
Connecticut (135)
Europe (87420)
Florida (421)
Georgia (104)
Illinois (331)
Indiana (198)
Kansas (96)
Maryland (555)
Massachusetts (2426)
Michigan (147)
Minnesota (259)
New Jersey (886)
New York (881)
North Carolina (718)
Northern California (1316)
Ohio (132)
Pennsylvania (784)
South America (1179)
Southern California (1171)
Texas (417)
Washington State (344)
711,188 Results for "ascendis pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Ascendis Pharma Reports First Quarter 2024 Financial Results
Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2024, and provided a business update.
May 2, 2024
·
12 min read
Press Releases
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
November 8, 2024
·
3 min read
Rare diseases
Ascendis’ Hypoparathyrodism Drug Secures FDA Approval Following Tough Regulatory Path
Ascendis Pharma’s palopegteriparatide was previously rejected by the regulator due to manufacturing problems, and the review period for its resubmitted application was extended by three months.
August 12, 2024
·
2 min read
·
Tristan Manalac
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024, at 8:00 a.m. ET in Miami, Florida.
June 4, 2024
·
3 min read
Press Releases
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
November 5, 2024
·
6 min read
GLP-1
Novo Nordisk Signs $285M GLP-1 Deal With Danish Neighbor Ascendis
In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon technology platform in an effort to find novel GLP-1 candidates with reduced dosing frequency.
November 4, 2024
·
1 min read
·
Annalee Armstrong
Press Releases
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
September 20, 2024
·
5 min read
Press Releases
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
September 19, 2024
·
5 min read
Business
Ascendis Pharma Reports Second Quarter 2024 Financial Results
September 3, 2024
·
14 min read
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
Ascendis Pharma A/S reported new and updated results from its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 β⁄γ in a poster presentation at ASCO 2024, the annual meeting of the American Society of Clinical Oncology being held in Chicago May 31–June 4, 2024.
June 3, 2024
·
7 min read
1 of 71,119
Next
